Article

Dr. Marcus Wilson Discusses How Comparative Effectiveness Research is Used in the Managed Care Setting

Marcus D. Wilson, PharmD, President, HealthCore, states that there is variability within and between different organizations that utilize comparative effectiveness research.

Marcus D. Wilson, PharmD, President, HealthCore, states that there is variability within and between different organizations that utilize comparative effectiveness research.

Comparative effectiveness research is used to better understand populations impacted by decisions, and is used to customize policy for specific populations.

Related Videos
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Tiara Green, MSEd
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
Rachel Dalthorp, MD
Quint and Petris
Andrew Cournoyer
Rebecca Flynn, Peter Lio, Timothy Caulfield, and Nichole Halliburton at SPD 2024
Related Content
In the pooled analysis, ankylosing spondylitis was associated with a greater risk of cancer occurrence. | Image credit: Lila Patel - stock.adobe.com
July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty
The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.
Managed Care Cast logo
July 25th 2024

Dr Jason Spangler on Enhancing Equity in Health Technology Assessment

Brooke McCormick
On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.
ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases
July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw
These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.
Managed Care Cast: Frameworks for Advancing Health Equity
July 23rd 2024

Frameworks for Advancing Health Equity: Health Equity by Design

Giuliana Grossi
Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
dr diane mahoney
July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick
In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.
Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com
July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

Kyle Munz
The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo